Guardant Health, Inc. (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor’s molecular characteristics.
The company’s products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment. Guardant also offers Guardant Reveal, a blood-based test intended to help evaluate minimal residual disease and recurrence risk, as well as Shield, a blood test for colorectal cancer screening.
Guardant Health provides testing services to physicians, hospitals, health systems, biopharmaceutical companies and research organizations. Its services support patient care, clinical research and drug development, with operations and commercial activities serving customers in the United States and international markets.
The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, who have held senior leadership roles at Guardant Health. The company is headquartered in Palo Alto, California.
AI Generated. May Contain Errors.
Free GH Stock Alerts